Skip to main content
Premium Trial:

Request an Annual Quote

Capital Genomix and Blanchette Rockefeller Neurosciences Institute to Build Microarray Facility

NEW YORK, May 30 -- Capital Genomix and the Blanchette Rockefeller Neurosciences Institute plan to establish a microarray core facility, Capital said yesterday.

 

The facility, to be housed at JohnsHopkinsUniversity's Shady Grove campus in Gaithersburg, Md., will be headed by microarray researcher Pachiappan Manickam.

 

Capital, based in Chantilly, Va., holds a microarray service license from Affymetrix. The company expects the collaboration with BRNI will expand to include its own gene expression and antibody technologies, called GeneSystem320 and ImmunoMouse, respectively.

 

BRNI is a non-profit institute focusing on translational research in the area of Alzheimer's disease.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.